Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia

Sponsor
The Third People's Hospital of Chengdu
Study ID
NCT06562738
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Hetrombopag — DRUG
    Hetrombopag 7.5 mg, once a day, at bedtime for up to 14 days, drug administration was stopped when PLT≥100 ×10\^9/L, and take blood routine examination weekly, drug administration was resumed when PLT \< 100 ×10\^9/L. When PLT ≤30× 10\^9/L or ≥300 ×10\^9/L, take blood routine examination every 3 days.

Study Details

This is an investigator-initiated, single-arm, prospective clinical study to evaluate the efficacy and safety of heptapopal in the treatment of thrombocytopenia prior to elective surgery

Key Dates

Start date
Jun 1, 2024
Status verified
Aug 2024
Primary completion
Jan 31, 2025
Completion
Mar 31, 2025

Study Design

Enrollment
55 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental: Hetrombopag arm
    Takes Hetrombopag 7.5 mg/day at bedtime for at most 14 days.

Primary Outcome Measure

Platelet elevation [ Time Frame: up to 14 days ]

Central Contacts

Related Studies